CoChat

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib

Open access
Fernando, Romaine I., Hamilton, Duane H., Dominguez, Charli, David, Justin M., McCampbell, Kristen K., Palena, Claudia · 2106 · Oncotarget
Cited by 61

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

// Romaine I. Fernando 1 , Duane H. Hamilton 1 , Charli Dominguez 1 , Justin M. David 1 , Kristen K. McCampbell 1 , Claudia Palena 1 1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA Correspondence to: Claudia Palena, email: palenac@mail.nih.gov Keywords: erlotinib, tumor resistance, IL-8, epithelial-mesenchymal transition Received: October 02, 2015 Accepted: May 14, 2016 Published: May 27, 2016 ABSTRACT A signaling pathway that is frequently deregulated in human carcinomas and has been explored as a therapeutic target involves the activation of the epidermal growth factor receptor (EGFR). Inhibition of EGFR via the small molecule inhibitors erlotinib and gefitinib commonly results in tumor resistance, even in patients with EGFR-mutant tumors that initially show substantial clinical responses. This study was designed to broaden our understanding of the molecular mechanisms of acquired resistance to erlotinib in lung cancer cells bearing wild type or mutated EGFR. We report here that generation of erlotinib-resistant lung cancer cells in vitro resulted in a phenotypic alteration reminiscent of an epithelial-mesenchymal transition (EMT) concomitant with a robust upregulation of the IL-8/IL-8R axis. Our results also demonstrate that upregulation of p38 MAPK signaling is responsible for the enhanced IL-8 secretion in the erlotinib-resistant tumor cells. Blockade of IL-8 signaling effectively reduced mesenchymal features of the resistant cells and also markedly enhanced their susceptibility to erlotinib. These results provide a rationale for the development of new therapeutic approaches involving blockade of IL-8 signaling for the management of acquired resistance to EGFR inhibition in patients with lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.9662

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 61

Metadata

Authors
Fernando, R. I., Hamilton, D. H., Dominguez, C., David, J. M., McCampbell, K. K., & Palena, C.
Venue
Oncotarget
Published
2016-05-27
Volume
7
Issue
27
Pages
42031-42044
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2405571890
Cited by
61
References
13
FWCI
6.09
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. https://app.cochat.ai/papers/10.18632/oncotarget.9662
The paper
Fernando, R. I., Hamilton, D. H., Dominguez, C., David, J. M., McCampbell, K. K., & Palena, C. (2106). IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget. https://doi.org/10.18632/oncotarget.9662

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.